Tuesday’s News in Brief

30 April 2002

NetValue Annual Revenues Up 90% but Posts €20.5mLoss
French-based international web research agency NetValue on Friday reported consolidated annual revenues for 2001 up by 90% to €6.58 million ($5.93m; £4.07m) but posted a net loss after minority interests of €20.5m. This includes non-recurrent and restructuring expenses of €7.6 million and compares favourably with a loss of €20.7m in 2000. The company, which has operations across Europe as well as the US and four Asia Pacific nations, believes it will benefit from the restructuring during the current fiscal and predicts a return to the black in 2003.

Data sourced from: Daily Research News Online; additional content by WARC staff

Asia Pacific
Yahoo Japan Doubles Fiscal Net Profit
Yahoo! Japan reported Friday that group net profit in the fiscal year to March 31 had almost doubled to ¥5.87 billion ($0.045bn; €0.050bn; £0.031bn). Revenues rose by 121% to ¥31.5 bn thanks to the weakness in advertising income being offset by robust performances in its new broadband and online auction operations.

Data sourced from: The Wall Street Journal Online; additional content by WARC staff

Euro Won’t Debase UK’s Brand Identity, Say Marketers
According to research agency ORC International, two-thirds of UK marketers do not believe abandoning the pound in favour of the Euro would debase “the unique essence of Britain's brand identity”. However, 15% observed at the pound is one of the world’s most stable currencies and that Britain would lose status if it switched to the Euro. Eleven per cent of the sample also said that even if the dumping of the pound did have a negative effect on the nation’s identity, this would be an acceptable sacrifice to protect future economic prosperity.
Data sourced from: Daily Research News Online; additional content by WARC staff

EC Mulls Liberalisation of Drug Ad Rules
Relaxation of the rules governing the advertising of certain prescription drugs to consumers are under consideration by the European Commission. Under scrutiny are drugs treating asthma diabetes and AIDS – much to the chagrin of critics who see the concession as the thin end of a wedge that will ultimately lead to full scale brand advertising. The EC denies this, saying that it plans only to permit drugs companies to target information on these disorders directly at patients.

Data sourced from: BBC Online Business News (UK); additional content by WARC staff